Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade

BACKGROUND: Immune-checkpoint-inhibitors (ICIs) have become the cornerstone of metastatic renal-cell-carcinoma (mRCC) therapy. However, data are limited regarding clinical outcomes by race. In this study, we compared the real-world outcomes between African American (AA) and Caucasian mRCC patients t...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Front Oncol
Auteurs principaux: Olsen, T. Anders, Martini, Dylan J., Goyal, Subir, Liu, Yuan, Evans, Sean T., Magod, Benjamin, Brown, Jacqueline T., Yantorni, Lauren, Russler, Greta Anne, Caulfield, Sarah, Goldman, Jamie M., Harris, Wayne B., Kucuk, Omer, Carthon, Bradley C., Master, Viraj A., Nazha, Bassel, Bilen, Mehmet Asim
Format: Artigo
Langue:Inglês
Publié: Frontiers Media S.A. 2021
Sujets:
Oncology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8242950/
https://ncbi.nlm.nih.gov/pubmed/34222024
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.701345
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires